NCT04521361 - A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

October 10, 2023

Study Completion Date

August 27, 2025

Conditions

Bone Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).

Trial Locations (12)

Uniklinikum Salzburg - Landeskrankenhaus, Salzburg

Institut Claudius Regaud - iUCT Oncopole, Toulouse

ICM - Institut du Cancer de Montpellier - Val d'Aurelle, Montpellier

Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale, Reggio Emilia

Institut de Cancerologie Ouest - Saint-Herblain, Saint-Herblain

HCL - Centre Hospitalier Lyon Sud, Pierre-Bénite

Rambam Health Corporation, Haifa

National Cancer Institute, Vilnius

Vilnius University Hospital Santaros Klinikos, Vilnius

Royal Marsden NHS Trust (Surrey), Sutton

University College London Hospitals NHS Foundation Trust, London

Guy's and St. Thomas' NHS Trust, St. Thomas' Hospital, London